News

-Collaboration will study how CCL24, a soluble protein involved in profibrotic and proinflammatory processes, contributes to the vascular damage related to systemic sclerosis (SSc)-

Dr. Adi Mor continues as Chief Scientific Officer, directing scientific strategy and overseeing R&D operations

- CM-101 Phase 2a trials in PSC and liver fibrosis continue to enroll patients with data expected in 2022 -

AGC Biologics to manufacture CM-101 for Phase II/III trials at their Copenhagen facility

Announced positive data from its Phase Ib SPARK study evaluating CM-101 in NAFLD patients

The study aims to further validate the anti-fibrotic and anti-inflammatory activity of CM-101 while providing safety and PK data to support development of the subcutaneous formulation